September 26, 2016 6:48 PM ET

Biotechnology

Company Overview of Applied Genetic Technologies Corporation

Company Overview

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops genetic therapies to treat patients with inherited diseases. Its lead products consist of four ophthalmology development programs across three targets, including X linked retinoschisis (XLRS) that is in a Phase I/II clinical trials for the treatment of an inherited retinal disease; X-linked retinitis pigmentosa (XLRP), which is enrolling patients in a Phase I/II clinical trials; and achromatopsia (ACHM) that is enrolling patients in a Phase I/II clinical trials. Applied Genetic Technologies Corporation has collaboration agreements with Biogen MA, Inc.; 4D Molecular Therapeutics; and Synpromics Limited....

14193 NW 119th Terrace

Suite 10

Alachua, FL 32615

United States

Founded in 1999

53 Employees

Phone:

386-462-2204

Key Executives for Applied Genetic Technologies Corporation

Chief Executive Officer, President and Director
Age: 55
Total Annual Compensation: $400.0K
Chief Financial Officer
Age: 60
Total Annual Compensation: $300.0K
Chief Medical Officer and Vice President
Age: 69
Total Annual Compensation: $350.0K
Chief Business Officer and Vice President
Age: 60
Total Annual Compensation: $127.1K
Chief Scientific Officer
Age: 56
Total Annual Compensation: $79.2K
Compensation as of Fiscal Year 2015.

Applied Genetic Technologies Corporation Key Developments

Applied Genetic Technologies Announces Unaudited Earnings Results for Fourth Quarter and Full Year Ended June 30, 2016

Applied Genetic Technologies announced unaudited earnings results for fourth quarter and full year ended June 30, 2016. For the quarter, the company reported total revenue of $12,113,000, income from operations of $2,487,000, net income of $2,728,000 or $0.15 basic and diluted per share, compared to the total revenue of $713,000, loss from operations of $8,030,000, net loss of $7,961,000 or $0.48 basic and diluted per share, for the same quarter a year ago. For the year, the company reported total revenue of $47,361,000, loss from operations of $2,089,000, net loss of $1,381,000 or $0.08 basic and diluted per share, compared to the total revenue of $2,354,000, loss from operations of $24,532,000, net loss of $24,318,000 or $1.5 basic and diluted per share, for the previous year.

Applied Genetic Technologies Corporation to Report Q4, 2016 Results on Sep 12, 2016

Applied Genetic Technologies Corporation announced that they will report Q4, 2016 results at 5:00 PM, Eastern Standard Time on Sep 12, 2016

Applied Genetic Technologies Corporation, Q4 2016 Earnings Call, Sep 12, 2016

Applied Genetic Technologies Corporation, Q4 2016 Earnings Call, Sep 12, 2016

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Applied Genetic Technologies Corporation, please visit www.agtc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.